Cleveland, OH — If you’re like us, the bottom of your inbox is usually cluttered with emails you really mean to get back to, including lots of newsletters and alerts full of great research and insight. With more emails arriving every moment, it’s hard to ever catch up. So, as part of our new year’s resolutions, we read them all and found three you will not want to miss:

  1. PwC conducted new research into what patients want today
  2. CMI/Compas got doctors’ reactions to The Sunshine Act
  3. Rock Health showed us where the digital health investment is

Here are the highlights (and, don’t save this for later!)

Ok, the big one first:

#1 PwC: Customer Experience In the Pharmaceutical Sector

More than 700 U.S. consumers and several leaders at retail and pharma brands contributed to this report about starting and sticking with medication. The landscape has really changed. Of course, there are still many consumers who have limited veto power over the type and price of medication they take, but there’s also a growing segment who have high-deductible insurance plans and are much less passive consumers of pharmaceuticals.

On both sides of the market, consumers have strong views on the pharma industry and big expectations for it should evolve to deliver experiences more like the ones they have with brands in other categories.

In other words, today’s patient is moving from a passive recipient of healthcare to an independent decision maker. That’s creating a lot of interesting new behaviors – and, some very familiar old ones.

Oh, and one other thing: Here’s a new dictionary of all the industry slang around how people really (don’t) use as directed:

Get the PwC report.

 #2 CMI/Compas: The Sunshine Act

You’ve probably already heard a lot of talk about The Physician Payment Sunshine Act. It creates new reporting rules for exchanges of value between pharma and physicians.

Want more on the Act? Here’s a great summary.

To understand more about how the law will change the industry, CMI/Compas interviewed both primary care physicians and pharma industry experts to understand their perspectives. They identified gaps in both understanding and expectation.

Even when the rules were explained, physicians didn’t expect to radically change their behavior. There’s a lot they value and still need from pharma, but participation with some offerings will decrease.

Get the CMI report.

#3 Rock Health: 2013 Digital Health Funding Report

Rock Health is one of the biggest names in venture capital for digital health. And, they’re a go-to source for knowing where investors are placing their bets. Since their first report in 2011, digital health funding has more than doubled — exceeding $1.9B with 195 venture deals ($2M+) in 2013. In 2014, the digital health industry is set to surpass total medical device venture funding. Pretty cool, right?

186 digital health companies each raise $2 million in 2013, but these deals were the biggest of the big:

See the full Rock Health report


Posted by: Leigh Householder

Contributors: Ritesh Patel, Patrick Richard, George Van Antwerp

About the Author:

As Managing Director of Innovation and Insights for Syneos Health Communications, Leigh is responsible for building and scaling a global team of healthcare experts who together help life science leaders better understand the complex lives, influences and expectations of their customers. Specifically, they uncover actionable insights that fuel empathy and creativity; lead co-creation events that let marketers learn from peers, trends, and new possibilities; and help clients identify the most valuable and useful new customer experiences to create.

Leigh has worked with Fortune 1000 companies to craft their digital, mobile, social and CRM strategies for nearly 20 years.She’s worked for category-leading agencies in retail, public affairs, B2B technology, and higher education. Prior to moving to Syneos Health Communications, she held several leadership roles at our largest agency, GSW.  There, she founded an innovation practice fueled by the zeitgeist and spearheaded digital and innovation thinking across the business.

Leigh has taken a special interest in complex healthcare products that can change lives in meaningful ways. She was recently a strategic lead on the 3rd largest launch in pharmaceutical history: Tecfidera. Before that she had keys roles with Eli Lilly Oncology, Abbott Nutrition, Amgen Cardiovascular, and Eli Lilly Diabetes.

A critical part of Leigh’s work is trends and new ideas. Every year, she convenes a group of trend watchers from across our global network to identify the shifts most critical to healthcare marketers. This year, she led over 250 experts to experts to focus on the most important changes in the commercial, consumer, marketing, digital and healthcare landscapes. (See reports at

Leigh is a sought-after writer and speaker. Recognized as one of the most inspiring people in the pharmaceutical industry by PharmaVoice and Top 10 Innovation Catalysts of 2017 by MM&M, Leigh also was recognized  as a Rising Star by the Healthcare Businesswomen's Association (HBA) for her overt passion, industry thought leadership and significant contributions in new business, strategy and mentoring.